Akoya Biosciences Newsroom

Akoya Biosciences And NeraCare Sign Exclusive Global License Agreement To Develop And Commercialize Immunoprint Test For Early-Stage Melanoma Treatment Decisions, Leveraging Akoya's PhenoImager HT Platform To Address High-Risk Relapse Patients With...

BenzingaDec 10 21:16

Express News | Akoya Biosciences and Neracare Enter Into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

BreakingsDec 10 21:15

Akoya Biosciences and NeraCare Enter Into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

GlobeNewswireDec 10 21:15

Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone

GlobeNewswireDec 9 21:00

Not Many Are Piling Into Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Yet As It Plummets 33%

Simply Wall StDec 6 18:20

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

PR NewswireDec 2 23:18

Piper Sandler Maintains Akoya Biosciences(AKYA.US) With Buy Rating, Cuts Target Price to $3

Futu NewsNov 19 20:31 · Ratings

Time To Worry? Analysts Just Downgraded Their Akoya Biosciences, Inc. (NASDAQ:AKYA) Outlook

Simply Wall StNov 19 18:46

Morgan Stanley Maintains Akoya Biosciences(AKYA.US) With Hold Rating, Maintains Target Price $3

Futu NewsNov 19 16:36 · Ratings

12 Health Care Stocks Moving In Friday's Pre-Market Session

BenzingaNov 16 05:06

Akoya Stock Plunges 30% on Outlook as Craig-Hallum Cuts to Hold

Seeking AlphaNov 16 03:59

Akoya Biosciences Is Maintained at Buy by Canaccord Genuity

Dow JonesNov 15 22:21 · Ratings

Akoya Biosciences Analyst Ratings

BenzingaNov 15 22:11 · Ratings

Piper Sandler Maintains Akoya Biosciences(AKYA.US) With Buy Rating, Maintains Target Price $4

Futu NewsNov 15 21:31 · Ratings

Craig-Hallum Downgrades Akoya Biosciences(AKYA.US) to Hold Rating, Announces Target Price $5

Futu NewsNov 15 21:31 · Ratings

Akoya Biosciences Shares Sink After FY24 Outlook Cut

WSJNov 15 21:22

Piper Sandler Keeps Their Buy Rating on Akoya Biosciences (AKYA)

TipRanksNov 15 20:07 · Ratings

CCORF Maintains Akoya Biosciences(AKYA.US) With Buy Rating, Cuts Target Price to $3.5

Futu NewsNov 15 18:34 · Ratings

Express News | Akoya Biosciences Inc : Canaccord Genuity Cuts Target Price to $3.50 From $6

BreakingsNov 15 15:50

Akoya Biosciences, Inc. (AKYA) Q3 2024 Earnings Call Transcript Summary

Futu NewsNov 15 10:50 · Conference Call